Lumira and BDC co-lead Zymeworks Inc.’s US$ 61.5 million Series A mezzanine financing

Lumira and BDC co-lead Zymeworks Inc.’s US$ 61.5 million Series A mezzanine financing
January 08
10:48 2016

Zymeworks Inc. today announced the closing of a US$ 61.5 million Series A mezzanine financing to support the advancement of its Azymetric™ therapeutics pipeline.

The financing was co-led by new investors BDC Capital and Lumira Capital, and joined by existing Zymeworks investors Eli Lilly and Company, Celgene, CTI Life Sciences Fund, and the Fonds de solidarité FTQ. New investors in the financing include Perceptive Advisors, Teralys Capital, Northleaf Venture Catalyst Fund, Brace Pharma Capital, Merlin Nexus and others. Proceeds of the financing will support clinical development of Zymeworks’ lead therapeutic candidates, ZW25 and ZW33, which the Company plans to move into clinical development later this year.

Press release

Share

Related Articles

SIGN UP FOR DAILY DEALS AND NEWS UPDATE

CVCA Events

CVCA on Twitter